FEDERAL COURT OF AUSTRALIA
Regeneron Pharmaceuticals, Inc. v Sandoz Pty Ltd [2025] FCA 1067
Keep reading for free
Create a free CaseChat account to read Regeneron Pharmaceuticals, Inc. v Sandoz Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2025] FCA 1067
- Decision Date
CaseChat Overview and Summary
The court found that Regeneron had not demonstrated a strong likelihood of success on the merits of their infringement claims, as the construction of the patent claims was not sufficiently clear to conclude that Sandoz's product would infringe. Additionally, the validity of the patents was challenged on grounds of novelty and inventive step, which the court considered to be contentious issues that would likely be resolved in Sandoz's favour. Regarding the balance of convenience, the court noted that the appeal process would significantly delay any final determination, diminishing any advantage Regeneron might have as a first mover in the market. Consequently, the court determined that the balance of convenience did not favour granting the interim relief sought by Regeneron.
The court dismissed Regeneron's application for interlocutory injunctive relief. The reasons for the judgment were to be kept confidential, with the parties to propose redactions for sensitive information. If the parties could not agree on the redactions, they were to list their respective proposals. Costs were reserved pending further directions.
Orders
Orders of the court
1. The Applicants’/ Cross Respondents’ claim for interlocutory relief in paragraphs 11 to 14 of its Amended Originating Application dated 8 August 2025 be dismissed.
2. Until further order, the Court’s reasons for judgment not be disclosed to or published by any person, save for the parties’ legal representatives and Court staff.
3. Within fourteen days, the parties confer, prepare and provide to the Chambers of Justice Rofe, proposed redactions to the reasons for judgment in relation to paragraphs that contain confidential information.
4. If the parties are unable to agree on the proposed redactions referred to in order 3, each of the parties should file and serve on or before 29 September 2025:
(a) a list of paragraphs of the agreed redactions; and
(b) a list of paragraphs each of the parties consider ought to be redacted.
5. Costs be reserved.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
The Sandoz PI provides the following in relation to Wet AMD and DME:The interval between doses injected into the same eye should not be shorter than one month.Advice on treatment initiation and maintenance of therapy specific to each patient population is described in the section below. Once optimal visual acuity is achieved and/or there are no signs of disease activity, treatment may then be continued with a treat-and-extend regimen with gradually increased treatment intervals to maintain stable visual and/or anatomic outcomes. If disease activity persists or recurs, the treatment interval may be shortened accordingly. Monitoring should be done at injection visits. The monitoring and treatment schedule should be determined by the treating ophthalmologist based on the individual patient’s response. If visual and anatomic outcomes indicate that the patient is not benefiting from continued treatment, AFQLIR should be discontinued. • Treatment of neovascular (wet) age-related macular degeneration (wet AMD)AFQLIR 2 mg treatment is initiated with one AFQLIR 2 mg injection per month for three consecutive months, followed by one injection every two months.Based on the physician’s judgement of visual and/or anatomic outcomes, the treatment interval may be maintained at two months or further extended using a treat-and-extend dosing regimen, by increasing injection intervals in 2- or 4-weekly increments while maintaining stable visual and/or anatomic outcomes. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened to a minimum of four weeks based on anatomical and/or visual outcomes. […]• Treatment of diabetic macular oedema (DME)AFQLIR 2 mg treatment is initiated with one AFQLIR 2 mg injection per month for five consecutive months.Following the initiation period and based on the physician’s judgement of visual and/or anatomic outcomes, the treatment interval may then be maintained at an injection every two months or further individualised, such as with a treat-and-extend dosing regimen, by increasing injection intervals in 2- or 4-weekly increments while maintaining stable visual and/or anatomic outcomes. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly. Treatment intervals shorter than 4 weeks or longer than 4 months have not been studied (see Section 5.1 Pharmacodynamic properties, Clinical trials). (Emphasis added in italics.) (Emphasis in original in bold.) In addition to Wet AMD and DME, the Sandoz PI also discusses treatment using the Sandoz Aflibercept Products for CRVO, BRVO and CNV.3.4.2Ophthalmologist treatment regimens for EYLEA® 2mg A/Prof Wickremasinghe currently uses EYLEA® 2mg as his standard treatment for both Wet AMD and DME. He uses what he describes as a “treat-and-extend” strategy which he considers to be the standard treatment strategy for Wet AMD in the Australian ophthalmology community. A/Prof Wickremasinghe notes that because the treatment of DME is less predictable, “a treat-and-extend strategy can be less useful in DME (although for some patients, it is appropriate)”.